Missouri Attorney General Issues Cease-and-Desist to Eli Lilly

Missouri Attorney General Targets Eli Lilly Drug Pricing Policy

The missouri attorney general has issued a formal cease-and-desist order against prescription manufacturer Eli Lilly. The state's top legal office alleges that the pharmaceutical company has placed unlawful demands on medical facilities involved in the federal 340B Drug Pricing Program.

According to the announcement, the dispute centers on a corporate policy requiring hospitals to surrender extensive and sensitive claims data in exchange for discounted medications. State officials report that this requirement effectively blocked participating facilities from receiving proper discounts.

Impact on MU Health Care and Rural Communities

The enforcement action follows a pricing dispute involving MU Health Care. After the health system initially declined to provide the requested claims data, Eli Lilly terminated its access to 340B pricing structures in July.

To prevent further financial losses and mitigate risks to patient care, MU Health temporarily agreed to supply the requested information. State leadership emphasized that rural communities rely heavily on these federal pricing discounts to maintain clinic operations and secure necessary treatments for patients.

Next Steps and Consumer Reporting

State officials maintain that large pharmaceutical companies should not use market power to pressure regional medical providers or increase prescription costs. The attorney general's office has invited anyone affected by these questionable pharmaceutical practices to submit a formal complaint through the official state website.

Sources: KMOV, ABC17NEWS, KCTV.